After IPO Success, Apogee Prepares To Take On Lilly And Sanofi Dupixent Across I&I

Using a 'de-risked business model' of targeting established drug categories with next-generation antibodies, Apogee is looking to take on Lilly’s lebrikizumab and Sanofi’s Dupixent.